Future Science OA (Jun 2021)

Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case–control study

  • Yael N Kusne,
  • Heidi E Kosiorek,
  • Matthew R Buras,
  • Patricia M Verona,
  • Kyle E Coppola,
  • Kelley A Rone,
  • Curtiss B Cook,
  • Nina J Karlin

DOI
https://doi.org/10.2144/fsoa-2020-0190
Journal volume & issue
Vol. 7, no. 5

Abstract

Read online

Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control. Patients & methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005–2017), and survival compared (Kaplan–Meier and Cox proportional hazards). Mixed models compared hemoglobin A1c (HbA1c) and glucose during the year after cancer diagnosis. Results: Three-year overall survival was 72% (95% CI: 60–86%) for DM patients versus 80% (95% CI: 70–92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56–3.16; p = 0.51); mean DM HbA1c, 7.3%. Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.

Keywords